News

BioControl Medical, a medical device company headquartered in Yehud, Israel, has received approval from the Israel Ministry of Health to conduct a clinical trial of its CardioFit® system in patients with chronic heart failure (HF) as part of...

New CE-marked Generator and 5 Fr Radial Artery Catheter bring innovation to the field of Renal Denervation ReCor Medical announced major advances in its Paradise System™ for renal denervation (RDN), confirming its commitment to lead in the...

Implant of retrievable leadless pacemaker represents important milestone in pacemaker history St. Jude Medical, Inc., a global medical device company, announced the first post-approval implant of the Nanostim™ leadless pacemaker in the U.K....

Study to Evaluate Safety and Effectiveness of Pacing System with Full-body ProMRI® Technology Moving Forward Rapidly BIOTRONIK, a leading manufacturer of cardiovascular medical devices, announced that the first patients have been enrolled in...

WHAT: The Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center will host EP Live — a two-day, intensive educational meeting targeting practicing electrophysiologists from across the globe, electrophysiology (EP) fellows in...

New findings from the ECOST study underscore the economic benefits of BIOTRONIK Home Monitoring® for the French National Health Insurance system BIOTRONIK Home Monitoring® significantly reduces the cost of follow-up in patients with...

Virginia Cardiovascular Specialists at Levinson Heart Hospital in Richmond, Virginia treated first patient in superiority study to evaluate persistent atrial fibrillation nContact, Inc. announced the first patient treated in the CONVERGE...

University Medical Center Ljubljana Reports Longest Convergent Procedure Follow-Up to Date at the Atrial Fibrillation Symposium 19th Annual Meeting A new physician poster presentation at the Atrial Fibrillation Symposium 19th Annual...

February is American Heart Month, a month to focus on a disease that kills more than 600,000 Americans each year. Every 39 seconds someone in the United States dies from heart disease,* while sudden cardiac arrest (SCA) claims one life every...

Phase 2B/3 GENETIC-AF Trial on Track to Begin Patient Enrollment in Q1 2014 Gencaro Potentially the First Genetically-Targeted Cardiovascular Treatment ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted...